303 results on '"Nandakumar, Subhiksha"'
Search Results
2. CDKN2A/B mutations and allele-specific alterations stratify survival outcomes in IDH-mutant astrocytomas
3. Gene-based Confirmatory Germline Testing Following Tumor-only Sequencing of Prostate Cancer
4. Utility of circulating tumor DNA (ctDNA) from cerebrospinal fluid (CSF) for prognosis of patients with recurrent high grade glioma.
5. Tracking the FDA precision oncology drug approval landscape in OncoKB.
6. CEACAM5-Targeted Immuno-PET in Androgen Receptor–Negative Prostate Cancer
7. Supplementary Table S6 from Integrative Molecular Analyses of the MD Anderson Prostate Cancer Patient-derived Xenograft (MDA PCa PDX) Series
8. Data from Integrative Molecular Analyses of the MD Anderson Prostate Cancer Patient-derived Xenograft (MDA PCa PDX) Series
9. Supplementary Figure S4 from Integrative Molecular Analyses of the MD Anderson Prostate Cancer Patient-derived Xenograft (MDA PCa PDX) Series
10. BRCA mutational status shapes the stromal microenvironment of pancreatic cancer linking clusterin expression in cancer associated fibroblasts with HSF1 signaling
11. Prognostic and therapeutic significance of COP9 signalosome subunit CSN5 in prostate cancer
12. Integrative Molecular Analyses of the MD Anderson Prostate Cancer Patient-derived Xenograft (MDA PCa PDX) Series
13. Tumor Volume Growth as Surrogate Endpoint in IDH-mt Glioma—Response
14. Abstract C074: Clinico-genomic characterization of N=2,460 pancreatic adenocarcinoma identifies KRASMUT dosage as prognostic of overall survival across disease stages
15. Figure S1 from Quantifying the Expanding Landscape of Clinical Actionability for Patients with Cancer
16. Table S3 from Quantifying the Expanding Landscape of Clinical Actionability for Patients with Cancer
17. Data from Tumor Volume Growth Rates and Doubling Times during Active Surveillance of IDH-mutant Low-Grade Glioma
18. Supplementary Table S2 from Tumor Volume Growth Rates and Doubling Times during Active Surveillance of IDH-mutant Low-Grade Glioma
19. Supplementary Figure S3 from Tumor Volume Growth Rates and Doubling Times during Active Surveillance of IDH-mutant Low-Grade Glioma
20. Tumor Volume Growth Rates and Doubling Times during Active Surveillance of IDH-mutant Low-Grade Glioma
21. MODL-37. MODELING REVERSIBLE TUMORIGENESIS IN CEREBRAL ORGANOIDS
22. PATH-27. DROPLET DIGITAL PCR ENHANCES DETECTION OF HOTSPOT MUTATIONS IN CIRCULATING TUMOR DNA FROM CEREBROSPINAL FLUID OF PATIENTS WITH HIGH-GRADE GLIOMA
23. PR046/#280 The genomic landscape of distant metastatic endometrial cancer
24. NIMG-38. TUMOR VOLUME GROWTH RATES AND DOUBLING TIMES DURING ACTIVE SURVEILLANCE OF IDH-MUTANT LOW-GRADE GLIOMA
25. Quantifying Y chromosome loss in primary and metastatic prostate cancer by chromosome painting.
26. Quantifying the Expanding Landscape of Clinical Actionability for Patients with Cancer
27. Supplementary Data from Tumor MHC Class I Expression Associates with Intralesional IL2 Response in Melanoma
28. Supplementary Figure from Genetic Ancestry Correlates with Somatic Differences in a Real-World Clinical Cancer Sequencing Cohort
29. Data from Tumor MHC Class I Expression Associates with Intralesional IL2 Response in Melanoma
30. Supplementary Data from Genetic Ancestry Correlates with Somatic Differences in a Real-World Clinical Cancer Sequencing Cohort
31. Data from Genetic Ancestry Correlates with Somatic Differences in a Real-World Clinical Cancer Sequencing Cohort
32. Abstract 1053: Circulating tumor DNA from cerebrospinal fluid (CSF) allows for characterization and monitoring of glioma patients
33. Supplemental Table 2 from Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune Therapies
34. Supplementary Appendix from Attenuation of SRC Kinase Activity Augments PARP Inhibitor–mediated Synthetic Lethality in BRCA2-altered Prostate Tumors
35. Supplementary Figure from The Impact of PIK3R1 Mutations and Insulin–PI3K–Glycolytic Pathway Regulation in Prostate Cancer
36. Table S8 from Significance of BRCA2 and RB1 Co-loss in Aggressive Prostate Cancer Progression
37. Supplementary Data from A Novel Mechanism Driving Poor-Prognosis Prostate Cancer: Overexpression of the DNA Repair Gene, Ribonucleotide Reductase Small Subunit M2 (RRM2)
38. Supplemental Table 3 from Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune Therapies
39. Figure S2 from Significance of BRCA2 and RB1 Co-loss in Aggressive Prostate Cancer Progression
40. Figure S6 from A Novel Mechanism Driving Poor-Prognosis Prostate Cancer: Overexpression of the DNA Repair Gene, Ribonucleotide Reductase Small Subunit M2 (RRM2)
41. Figure S2 from Attenuation of SRC Kinase Activity Augments PARP Inhibitor–mediated Synthetic Lethality in BRCA2-altered Prostate Tumors
42. Supplementary Figure from Differences in Prostate Cancer Genomes by Self-reported Race: Contributions of Genetic Ancestry, Modifiable Cancer Risk Factors, and Clinical Factors
43. Supplementary Tables 1-6 and Supplementary Figures 1-6 from Oncogenic Genomic Alterations, Clinical Phenotypes, and Outcomes in Metastatic Castration-Sensitive Prostate Cancer
44. Supplementary Data from Oncogenic Genomic Alterations, Clinical Phenotypes, and Outcomes in Metastatic Castration-Sensitive Prostate Cancer
45. Supplemental Table 1 from Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune Therapies
46. Data from Differences in Prostate Cancer Genomes by Self-reported Race: Contributions of Genetic Ancestry, Modifiable Cancer Risk Factors, and Clinical Factors
47. Supplemental Figure 1 from Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune Therapies
48. The Impact of PIK3R1 Mutations and Insulin–PI3K–Glycolytic Pathway Regulation in Prostate Cancer
49. Long-term Outcomes in Primary CNS Lymphoma After R-MVP and High-Dose Chemotherapy With Autologous Hematopoietic Stem Cell Transplant.
50. IncreasedMYBL2expression in aggressive hormone‐sensitive prostate cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.